Covid-19 Research

Research Article

Breakthrough Infection among Fully Vaccinated Physicians Working in COVID-19 Treatment Centers; Prevalence, Presenting Symptoms, Co-Morbidities and Outcome in the Third Wave of Epidemics in Myanmar

Journal of Biomedical Research & Environmental Sciences article abstract with citation details, DOI, publication dates, subject areas, full text links, and references.

View DOI Submit Manuscript

Article Details

Publication record, authors, dates, abstract, and full text access.

Open Access
Article Type Research Article
Subject Biology Group
OCLC 9227631818
Khin Phyu Pyar, Sai Aik Hla, Soe Min Aung, Di Wunn, Zar Ni Htet Aung, Nyan Lin Maung, Thurein Win, Linn Htet Aung, Aung Phyoe Kyaw, Kyaw Zay Ya, Thi Han Tun, Myo Thant Kyaw, Zaw Lin Oo, Zay Phyo Aung, Than Naing Lin and Soe Moe Htun
Issue: Volume2-Issue8
Pages: 721-730
Received: 2021-08-18
Accepted: 2021-08-24
Published: 2021-08-30

Abstract

Background: Coronavirus Disease 2019 (COVID-19), emerged in China at the end of 2019, became a major threat to health around the world. Breakthrough infection following COVID-19 vaccine has clinical and public health significance. The highest groups at risk of infection during the COVID-19 pandemic is health care workers; the physicians are the frontline workers. This study aimed to assess the prevalence of breakthrough COVID-19 infection and their clinical presentation, co-morbidities and outcome among physicians who were fully vaccinated, working in COVID-19 treatment centers in Myanmar.

Methods: A cross-sectional descriptive study was conducted among physicians, at least 14 days after receiving second dose, working at COVID-19 treatment centers in Myanmar, during the third wave from end of May to August 2021. Data were collected by using standardized forms and analysis was done.

Results: Among 410 physicians, 98.2% (221/225) received two dose of vaccination: Covaxin 90.0%, Covishield 9.5% and Sputink V 0.5%. They received first dose of vaccine in January/February 2021 and second dose in March/April 2021. In Myanmar, third wave started in end of May; the largest pandemic surge had reached its peak in July, 2021. In the third wave, most of them 72.9% (161/221) did not experience no infection. The prevalence of fully vaccinated break through infection was 27.1% (60/221); the majority 78.3% (47/60) were mild symptomatic infection. Severe infection was seen in 10% of physicians with breakthrough infection who required hospital admission and oxygen therapy. The common presenting symptoms in order of frequency were body aches and pain 62.6%, sneezing 56.6%, headache 53.5%, cough 52.5%, sore throat 45.5%, anosmia 33.3%, runny nose 23.2% and loose motion 27.3%. The uncommon symptoms were dyspnoea 9.1%, vertigo 6.1%, skin rash 5.1%, vomiting 5.1%, petechiae 3.0%, tinnitus 3.0% and silent hypoxia 3.0%, and non-per-os 1%. Most of them did not have any significant comorbidities. One out of six physicians having severe infection had diabetes mellitus and two were obese. The mean duration of hospital stay was 7 days. None of the cases was fatal.

Conclusions: In this study, over 98% of physicians were fully vaccinated; majority with Covaxin. One in four physicians had breakthrough infection in third wave; mainly mild form. Nearly half of them had possible delta symptoms; aches and pain, sneezing, runny nose, headache, cough, and sore throat. Awareness of rare but important symptoms like Non-per-Os and vertigo should be highlighted both to public and health care personnel. Ten percent of physicians with breakthrough infection were severe. Mortality rate was zero.

FullText HTML FullText PDF DOI: 10.37871/jbres1303 Crossmark

Certificate of Publication

Certificate of Publication

Copyright

© 2021 Pyar KP, et al. Distributed under Creative Commons CC-BY 4.0 Creative CommonsAttribution

How to cite this article

Pyar KP, Hla SA, Aung 3 SM, Wunn D, Htet Aung ZN, Maung NL, Win T, Aung LH, Kyaw AP, Ya KZ, Tun TH, Kyaw MT, Oo ZL, Aung ZP, Lin TN, Htun SM. Breakthrough Infection among Fully Vaccinated Physicians Working in COVID-19 Treatment Centers; Prevalence, Presenting Symptoms, Co-Morbidities and Outcome in the Third Wave of Epidemics in Myanmar. J Biomed Res Environ Sci. 2021 Aug 30; 2(8): 721-730. doi: 10.37871/jbres1303, Article ID: JBRES1303, Available at: https://www.jelsciences.com/articles/jbres1303.pdf

Subject area(s)

BiomedicineBiology

University/Institute

Defense Services Medical Academy

References

  1. WHO. WHO Coronavirus (COVID-19). 2021 Aug.
  2. https://tinyurl.com/22s2tzcj
  3. United Nations Population Division. Burma (Myanmar).
  4. https://tinyurl.com/7vtfvx2p
  5. MOHS. Coronavirus Disease 2019 (COVID-19) Surveillance Dashboard (Myanmar). 2021 Aug.
  6. https://tinyurl.com/2bx5jym8
  7. Robertson S. India’s whole-virion inactivated SARS-CoV-2 vaccine shows promise. News Medical Life Sciences. 2020.
  8. https://tinyurl.com/pamrwrjr
  9. Thiagarajan K. What do we know about India’s Covaxin vaccine? BMJ. 2021 Apr 20;373:n997. doi: 10.1136/bmj.n997. PMID: 33879478.
  10. Ella R, Vadrevu KM, Jogdand H, Prasad S, Reddy S, Sarangi V, Ganneru B, Sapkal G, Yadav P, Abraham P, Panda S, Gupta N, Reddy P, Verma S, Kumar Rai S, Singh C, Redkar SV, Gillurkar CS, Kushwaha JS, Mohapatra S, Rao V, Guleria R, Ella K, Bhargava B. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis. 2021 May;21(5):637-646. doi: 10.1016/S1473-3099(20)30942-7. Epub 2021 Jan 21. Erratum in: Lancet Infect Dis. 2021 Apr;21(4):e81. PMID: 33485468; PMCID: PMC7825810.
  11. Ella R, Reddy S, Jogdand H, Sarangi V, Ganneru B, Prasad S. Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up report. medRxiv. 2020.
  12. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, Stowe J, Tessier E, Groves N, Dabrera G, Myers R, Campbell CNJ, Amirthalingam G, Edmunds M, Zambon M, Brown KE, Hopkins S, Chand M, Ramsay M. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021 Aug 12;385(7):585-594. doi: 10.1056/NEJMoa2108891. Epub 2021 Jul 21. PMID: 34289274; PMCID: PMC8314739.
  13. Ghosh S, Shankar S, Chatterjee K, Chatterjee K, Yadav AK, Pandya K, Suryam V, Agrawal S, Ray S, Phutane V, Datta R. COVISHIELD (AZD1222) VaccINe effectiveness among healthcare and frontline Workers of INdian Armed Forces: Interim results of VIN-WIN cohort study. Med J Armed Forces India. 2021 Jul;77(Suppl 2):S264-S270. doi: 10.1016/j.mjafi.2021.06.032. Epub 2021 Jul 26. PMID: 34334892; PMCID: PMC8313084.
  14. Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, Caspi I, Levy R, Leshchinsky M, Ken Dror S, Bergerzon G, Gadban H, Gadban F, Eliassian E, Shimron O, Saleh L, Ben-Zvi H, Keren Taraday E, Amichay D, Ben-Dor A, Sagas D, Strauss M, Shemer Avni Y, Huppert A, Kepten E, Balicer RD, Netzer D, Ben-Shachar S, Stern A. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021 Aug;27(8):1379-1384. doi: 10.1038/s41591-021-01413-7. Epub 2021 Jun 14. PMID: 34127854.
  15. Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. Front Public Health. 2021 Jan 15;8:582932. doi: 10.3389/fpubh.2020.582932. PMID: 33520910; PMCID: PMC7844320.
  16. Tsai PH, Lai WY, Lin YY, Luo YH, Lin YT, Chen HK, Chen YM, Lai YC, Kuo LC, Chen SD, Chang KJ, Liu CH, Chang SC, Wang FD, Yang YP. Clinical manifestation and disease progression in COVID-19 infection. J Chin Med Assoc. 2021 Jan 1;84(1):3-8. doi: 10.1097/JCMA.0000000000000463. PMID: 33230062.
  17. Sheleme T, Bekele F, Ayela T. Clinical Presentation of Patients Infected with Coronavirus Disease 19: A Systematic Review. Infect Dis (Auckl). 2020 Sep 10;13:1178633720952076. doi: 10.1177/1178633720952076. PMID: 32973375; PMCID: PMC7495523.
  18. Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, Sun C, Sylvia S, Rozelle S, Raat H, Zhou H. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020 Mar 17;9(1):29. doi: 10.1186/s40249-020-00646-x. PMID: 32183901; PMCID: PMC7079521.
  19. Mehta OP, Bhandari P, Raut A, Kacimi SEO, Huy NT. Coronavirus Disease (COVID-19): Comprehensive Review of Clinical Presentation. Front Public Health. 2021 Jan 15;8:582932. doi: 10.3389/fpubh.2020.582932. PMID: 33520910; PMCID: PMC7844320.
  20. Almufarrij I, Munro KJ. One year on: an updated systematic review of SARS-CoV-2, COVID-19 and audio-vestibular symptoms. Int J Audiol. 2021 Mar 22:1-11. doi: 10.1080/14992027.2021.1896793. Epub ahead of print. PMID: 33750252.
  21. SeyedAlinaghi S, Mirzapour P, Dadras O, Pashaei Z, Karimi A, MohsseniPour M, Soleymanzadeh M, Barzegary A, Afsahi AM, Vahedi F, Shamsabadi A, Behnezhad F, Saeidi S, Mehraeen E, Shayesteh Jahanfar. Characterization of SARS-CoV-2 different variants and related morbidity and mortality: a systematic review. Eur J Med Res. 2021 Jun 8;26(1):51. doi: 10.1186/s40001-021-00524-8. PMID: 34103090; PMCID: PMC8185313.
  22. Rentsch CT, Kidwai-Khan F, Tate JP, Park LS, King JT Jr, Skanderson M, Hauser RG, Schultze A, Jarvis CI, Holodniy M, Re VL 3rd, Akgün KM, Crothers K, Taddei TH, Freiberg MS, Justice AC. Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans. medRxiv [Preprint]. 2020 May 18:2020.05.12.20099135. doi: 10.1101/2020.05.12.20099135. Update in: PLoS Med. 2020 Sep 22;17(9):e1003379. PMID: 32511524; PMCID: PMC7273292.
  23. Townsend MJ, Kyle TK, Stanford FC. Outcomes of COVID-19: disparities in obesity and by ethnicity/race. Int J Obes (Lond). 2020 Sep;44(9):1807-1809. doi: 10.1038/s41366-020-0635-2. Epub 2020 Jul 9. PMID: 32647359; PMCID: PMC7347050.
  24. Danchin A, Timmis K. SARS-CoV-2 variants: Relevance for symptom granularity, epidemiology, immunity (herd, vaccines), virus origin and containment? Environ Microbiol. 2020 Jun;22(6):2001-2006. doi: 10.1111/1462-2920.15053. Epub 2020 May 19. PMID: 32367648; PMCID: PMC7267449.
  25. Challen R, Brooks-Pollock E, Read JM, Dyson L, Tsaneva-Atanasova K, Danon L. Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study. BMJ. 2021 Mar 9;372:n579. doi: 10.1136/bmj.n579. PMID: 33687922; PMCID: PMC7941603.
  26. Graham MS, Sudre CH, May A, Antonelli M, Murray B, Varsavsky T, Kläser K, Canas LS, Molteni E, Modat M, Drew DA, Nguyen LH, Polidori L, Selvachandran S, Hu C, Capdevila J; COVID-19 Genomics UK (COG-UK) Consortium, Hammers A, Chan AT, Wolf J, Spector TD, Steves CJ, Ourselin S. Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health. 2021 May;6(5):e335-e345. doi: 10.1016/S2468-2667(21)00055-4. Epub 2021 Apr 12. PMID: 33857453; PMCID: PMC8041365.
  27. Htun YM, Win TT, Aung A, Latt TZ, Phyo YN, Tun TM, Htun NS, Tun KM, Htun KA. Initial presenting symptoms, comorbidities and severity of COVID-19 patients during the second wave of epidemic in Myanmar. Trop Med Health. 2021 Aug 6;49(1):62. doi: 10.1186/s41182-021-00353-9. PMID: 34362468; PMCID: PMC8343344.
  28. Ejaz H, Alsrhani A, Zafar A, Javed H, Junaid K, Abdalla AE, Abosalif KOA, Ahmed Z, Younas S. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020 Dec;13(12):1833-1839. doi: 10.1016/j.jiph.2020.07.014. Epub 2020 Aug 4. PMID: 32788073; PMCID: PMC7402107.
  29. Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M, Hauptmann K, Ingold-Heppner B, Miller F, Herbst H, Corman VM, Martin H, Radbruch H, Heppner FL, Horst D. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021 Feb 19;11(1):4263. doi: 10.1038/s41598-021-82862-5. PMID: 33608563; PMCID: PMC7895917.
  30. Ng WH, Tipih T, Makoah NA, Vermeulen JG, Goedhals D, Sempa JB, Burt FJ, Taylor A, Mahalingam S. Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. mBio. 2021 Feb 9;12(1):e03647-20. doi: 10.1128/mBio.03647-20. PMID: 33563817; PMCID: PMC7885108.
  31. Sharma P, Mishra S, Basu S, Tanwar N, Kumar R. Breakthrough infection with SARS-CoV-2 and its predictors among healthcare workers in a medical college and hospital complex in Delhi, India. medRxiv. 2021. doi: 10.1101/2021.06.07.21258447
  32. Niyas VKM, Arjun R. Response to letter re Breakthrough COVID-19 infections among health care workers after two doses of ChAdOx1 nCoV-19 vaccine. QJM. 2021 Jul 23:hcab204. doi: 10.1093/qjmed/hcab204. Epub ahead of print. PMID: 34297117; PMCID: PMC8344452.
  33. Butt AA, Nafady-Hego H, Chemaitelly H, Abou-Samra AB, Khal AA, Coyle PV, Kanaani ZA, Kaleeckal AH, Latif AN, Masalmani YA, Bertollini R, Raddad LJA. Outcomes Among Patients with Breakthrough SARS-CoV-2 Infection After Vaccination. Int J Infect Dis. 2021 Aug 8;110:353-358. doi: 10.1016/j.ijid.2021.08.008. Epub ahead of print. PMID: 34375762; PMCID: PMC8349447.
  34. Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Nesher L, Stein M, Maor Y, Cohen R, Hussein K, Weinberger M, Zimhony O, Chazan B, Najjar R, Zayyad H, Rahav G, Wiener-Well Y. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021 Jul 7:S1198-743X(21)00367-0. doi: 10.1016/j.cmi.2021.06.036. Epub ahead of print. PMID: 34245907; PMCID: PMC8261136.
  35. Sabetian G, Moghadami M, Hashemizadeh Fard Haghighi L, Shahriarirad R, Fallahi MJ, Asmarian N, Moeini YS. COVID-19 infection among healthcare workers: a cross-sectional study in southwest Iran. Virol J. 2021 Mar 17;18(1):58. doi: 10.1186/s12985-021-01532-0. PMID: 33731169; PMCID: PMC7968574.
  36. Tyagi K, Ghosh A, Nair D, Dutta K, Singh Bhandari P, Ahmed Ansari I, Misra A. Breakthrough COVID19 infections after vaccinations in healthcare and other workers in a chronic care medical facility in New Delhi, India. Diabetes Metab Syndr. 2021 May-Jun;15(3):1007-1008. doi: 10.1016/j.dsx.2021.05.001. Epub 2021 May 3. PMID: 33991805; PMCID: PMC8091733.
  37. Al-Kuwari MG, AbdulMalik MA, Al-Nuaimi AA, Abdulmajeed J, Al-Romaihi HE, Semaan S, Kandy M. Epidemiology Characteristics of COVID-19 Infection Amongst Primary Health Care Workers in Qatar: March-October 2020. Front Public Health. 2021 May 20;9:679254. doi: 10.3389/fpubh.2021.679254. PMID: 34095077; PMCID: PMC8173064.
  38. Barranco R, Ventura F. Covid-19 and infection in health-care workers: An emerging problem. Med Leg J. 2020 Jul;88(2):65-66. doi: 10.1177/0025817220923694. Epub 2020 May 22. PMID: 32441196.
  39. Schulte B, Marx B, Korencak M, Emmert D, Aldabbagh S, Eis-Hübinger AM, Streeck H. Case Report: Infection With SARS-CoV-2 in the Presence of High Levels of Vaccine-Induced Neutralizing Antibody Responses. Front Med (Lausanne). 2021 Jul 23;8:704719. doi: 10.3389/fmed.2021.704719. PMID: 34368197; PMCID: PMC8342944.
  40. Patil Y, Kesari M, Agrawal S, Dholpure M, Reheman, H. Post vaccination covid infection in health care workers at a tertiary care centre: A retrospective cohort study. Int J Contemp Med Res. 2021.
  41. https://tinyurl.com/5sxs8c
  42. Wayne WD, Daniel, Wayne W. Biostatistics-A Foundations for Analysis in the Health Sciences. Wiley & Sons, New York-Chichester-Brisbane-Toronto-Singapore, 6th ed. 1995;744-744.
  43. CDC COVID-19 Vaccine Breakthrough Case Investigations Team. COVID-19 Vaccine Breakthrough Infections Reported to CDC-United States. 2021.
  44. https://tinyurl.com/j7euth28
  45. Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, Mandelboim M, Gal Levin E, Rubin C, Indenbaum V, Tal I, Zavitan M, Zuckerman N, Bar-Chaim A, Kreiss Y, Regev-Yochay G. Covid-19 Breakthrough Infections in Vaccinated Health Care Workers. N Engl J Med. 2021 Jul 28:NEJMoa2109072. doi: 10.1056/NEJMoa2109072. Epub ahead of print. PMID: 34320281; PMCID: PMC8362591.
  46. Teran RA, Ghinai I, Gretsch S, Cable T, Black SR, Green SJ, Perez O, Chlipala GE, Cline MM, Kunstman KJ, Bleasdale SC, Fricchione MJ. COVID-19 Outbreak Among a University’s Men’s and Women’s Soccer Teams-Chicago, Illinois, July–August 2020. Morb Mo2rtal Wkly Rep. 2020;43:1591-1594.
  47. https://tinyurl.com/4vsfw5c
  48. Dash GC, Subhadra S, Turuk J, Parai D, Rath S, Sabat J, Rout UK, Kanungo S, Choudhary HR, Nanda RR, Pattnaik M, Pati S, Bhattacharya D. Breakthrough SARS-CoV-2 infections in an eastern state of India: A preliminary report. 2021. doi:10.21203/rs.3.rs-649914/v2
Publish with JBRES — Peer-reviewed, multidisciplinary Open Access with rapid review, DOI, and global visibility.
Double-Blind CrossRef DOI Discoverable
Submit Manuscript Membership